肿瘤细胞治疗研究
ALL SOURCES
Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.
本研究建立了一种快速、符合 GMP 要求的方法，可直接从全血制造多功能的 CAR-T 细胞。本文概述的工作流程获得了强效、表型有利的 CAR-T 细胞产品，且未损害活力或细胞毒性功能。与标准 7 天方法相比，3 天方案导致与更干细胞样表型相关的基因表达，同时缩短了生产时间并降低了成本。该方法可为分散式 CAR-T 细胞生产提供一种实用替代方案，尤其适用于资源有限的环境。
Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review.
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
Serpin B9 controls tumor cell killing by CAR T cells.
这些数据表明，serpin B9 是 CAR-T 细胞介导的肿瘤细胞杀伤的耐药介质，应通过抑制或绕过它来改善 CAR-T 细胞应答。
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
CD19/CD20 双靶向 CAR-NK 细胞的创建解决了 ALL 中因抗原异质性导致的肿瘤逃逸风险，提供了高效、安全的“现货型”细胞产品。这些细胞在 ALL 中靶向 CD20 和/或 CD19 抗原方面显示出疗效，为其在 ALL 治疗中的应用奠定了实验基础。
A Soluble NK-CAR Mediates the Specific Cytotoxicity of NK Cells toward the Target CD20(+) Lymphoma Cells.
The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i
The future of immunotherapy for diffuse large B-cell lymphoma.
Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges.
MEMBER ACCOUNT
登录成功会直接打开下一页。
